aztreonam has been researched along with Infections, Respiratory in 31 studies
Aztreonam: A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.
aztreonam : A synthetic monocyclic beta-lactam antibiotic (monobactam), used primarily to treat infections caused by Gram-negative bacteria. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidoglycan crosslinking.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A randomised double blind 2-week trial of monotherapy with ceftazidime and aztreonam was completed in 22 adults with cystic fibrosis." | 9.07 | A comparison of aztreonam and ceftazidime in the treatment of respiratory infections in adults with cystic fibrosis. ( Abbot, J; Bilton, D; Dodd, M; Salh, B; Webb, K, 1992) |
| "The efficacy of aztreonam was compared to that of standard therapy consisting of tobramycin and azlocillin in the treatment of acute pulmonary exacerbations of cystic fibrosis in a randomized, open trial." | 9.06 | Controlled trial of aztreonam vs. tobramycin and azlocillin for acute pulmonary exacerbations of cystic fibrosis. ( Black, PG; Bosso, JA, 1988) |
| "Aztreonam (E-0734, AZT) was administered to pneumonia and chronic respiratory tract infections." | 9.05 | [Clinical study of aztreonam on respiratory tract infections caused by gram-negative pathogens]. ( Hashigami, H; Kobayashi, T; Morishita, M; Sakai, S; Shimokata, K; Suetsugu, S; Tanaka, A; Totani, Y; Umeda, H; Yamamoto, M, 1985) |
| "A total of 80 patients were randomized to receive either aztreonam or tobramycin for the treatment of lower respiratory tract infections caused by gram-negative bacilli; all these patients received clindamycin concomitantly." | 9.05 | Efficacy and safety of aztreonam-clindamycin versus tobramycin-clindamycin in the treatment of lower respiratory tract infections caused by aerobic gram-negative bacilli. ( Nevárez, M; Ramírez-Ronda, CH; Rodríguez, JR, 1985) |
| "The in vitro activity of aztreonam and 10 other antibiotics was determined for clinical isolates of Pseudomonas aeruginosa from 18 cystic fibrosis patients obtained before, at the end of, and 7-14 days after the completion of therapy with aztreonam." | 7.67 | Absence of rapidly developing resistance during treatment of cystic fibrosis patients with aztreonam. ( Allen, JE; Bosso, JA; Matsen, JM; Saxon, BA, 1987) |
| "Aztreonam therapy was evaluated for the management of 80 patients with gram-negative bacilli lower respiratory tract infections." | 7.67 | Efficacy and safety of aztreonam versus tobramycin for aerobic gram-negative bacilli lower respiratory tract infections. ( Ramirez-Ronda, CH; Rodriguez, JR, 1985) |
| "However, bacteriological recurrence, related to the persistent nature of the underlying disease, occurred in 6 of the 10 patients during the 1-month follow-up period." | 6.65 | Clinical experience with aztreonam in urinary and respiratory tract infections. ( Donohoe, JF; Hollingsworth, JA; Hone, R; Keelan, PJ, 1984) |
| "Aztreonam was used in the initial treatment of infection of the urinary tract (23 cases), respiratory tract (17 cases), skin and soft tissue (12 cases), abdominal cavity (three cases), endocarditis (two cases), septicemia (eight cases), and osteomyelitis (two cases)." | 5.27 | Efficacy and safety of aztreonam in the treatment of serious gram-negative bacterial infections. ( Chandrasekar, P; Kannangara, W; LeFrock, JL; Molavi, A; Rolston, KV; Smith, BR, 1987) |
| "A randomised double blind 2-week trial of monotherapy with ceftazidime and aztreonam was completed in 22 adults with cystic fibrosis." | 5.07 | A comparison of aztreonam and ceftazidime in the treatment of respiratory infections in adults with cystic fibrosis. ( Abbot, J; Bilton, D; Dodd, M; Salh, B; Webb, K, 1992) |
| "The efficacy of aztreonam was compared to that of standard therapy consisting of tobramycin and azlocillin in the treatment of acute pulmonary exacerbations of cystic fibrosis in a randomized, open trial." | 5.06 | Controlled trial of aztreonam vs. tobramycin and azlocillin for acute pulmonary exacerbations of cystic fibrosis. ( Black, PG; Bosso, JA, 1988) |
| "Multicenter trials were conducted to determine the safety and efficacy of aztreonam in the treatment of patients with gram-negative bacterial infections." | 5.05 | Aztreonam: worldwide overview of the treatment of patients with gram-negative infections. ( Bendush, CB; Henry, SA, 1985) |
| "Aztreonam (E-0734, AZT) was administered to pneumonia and chronic respiratory tract infections." | 5.05 | [Clinical study of aztreonam on respiratory tract infections caused by gram-negative pathogens]. ( Hashigami, H; Kobayashi, T; Morishita, M; Sakai, S; Shimokata, K; Suetsugu, S; Tanaka, A; Totani, Y; Umeda, H; Yamamoto, M, 1985) |
| "A total of 80 patients were randomized to receive either aztreonam or tobramycin for the treatment of lower respiratory tract infections caused by gram-negative bacilli; all these patients received clindamycin concomitantly." | 5.05 | Efficacy and safety of aztreonam-clindamycin versus tobramycin-clindamycin in the treatment of lower respiratory tract infections caused by aerobic gram-negative bacilli. ( Nevárez, M; Ramírez-Ronda, CH; Rodríguez, JR, 1985) |
| "The pharmacokinetics of aztreonam were studied in ten critically ill intubated patients with lower respiratory tract infections." | 3.67 | The pharmacokinetics of aztreonam and penetration into the bronchial secretions of critically ill patients. ( Boccazzi, A; Langer, M; Mandelli, M; Ranzi, AM; Urso, R, 1989) |
| "The in vitro activity of aztreonam and 10 other antibiotics was determined for clinical isolates of Pseudomonas aeruginosa from 18 cystic fibrosis patients obtained before, at the end of, and 7-14 days after the completion of therapy with aztreonam." | 3.67 | Absence of rapidly developing resistance during treatment of cystic fibrosis patients with aztreonam. ( Allen, JE; Bosso, JA; Matsen, JM; Saxon, BA, 1987) |
| "Aztreonam therapy was evaluated for the management of 80 patients with gram-negative bacilli lower respiratory tract infections." | 3.67 | Efficacy and safety of aztreonam versus tobramycin for aerobic gram-negative bacilli lower respiratory tract infections. ( Ramirez-Ronda, CH; Rodriguez, JR, 1985) |
| "However, bacteriological recurrence, related to the persistent nature of the underlying disease, occurred in 6 of the 10 patients during the 1-month follow-up period." | 2.65 | Clinical experience with aztreonam in urinary and respiratory tract infections. ( Donohoe, JF; Hollingsworth, JA; Hone, R; Keelan, PJ, 1984) |
| "Aztreonam has proven to be effective, safe therapy for serious and life-threatening infections caused by multiresistant aerobic gram negative bacteria." | 2.37 | Aztreonam: the first monobactam. ( Neu, HC, 1988) |
| " Renal insufficiency may significantly impair the elimination of aztreonam, thus requiring modification of the dosage regimen." | 2.37 | Review of the clinical pharmacology of the monobactam antibiotic aztreonam. ( Swabb, EA, 1985) |
| " Tolerance to the drug was good in both groups, and in no instance did side effects necessitate modification of the dosing regimen." | 1.28 | The clinical use of aztreonam. ( Car, V; Krznar, B; Schönwald, S; Schoss-Vidensek, Z, 1989) |
| "Aztreonam was used in the initial treatment of infection of the urinary tract (23 cases), respiratory tract (17 cases), skin and soft tissue (12 cases), abdominal cavity (three cases), endocarditis (two cases), septicemia (eight cases), and osteomyelitis (two cases)." | 1.27 | Efficacy and safety of aztreonam in the treatment of serious gram-negative bacterial infections. ( Chandrasekar, P; Kannangara, W; LeFrock, JL; Molavi, A; Rolston, KV; Smith, BR, 1987) |
| "Aztreonam was the first compound to emerge that fulfilled the objectives of the program." | 1.27 | Aztreonam: the first monobactam. ( Bonner, DP; Sykes, RB, 1985) |
| "Aztreonam is a monocyclic beta-lactam antibiotic that inhibits aerobic gram-negative bacilli, including beta-lactamase-producing species." | 1.27 | Current state of infectious diseases--potential areas of directed therapy with aztreonam. ( Neu, HC, 1985) |
| "Clinical efficacy of AZT for 22 respiratory tract infections, 5 urinary tract infections and 2 gastrointestinal infections was "excellent" for 19 cases (65." | 1.27 | [Clinical study on aztreonam in pediatrics]. ( Kida, K; Matsuda, H; Murase, M; Niino, M, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 21 (67.74) | 18.7374 |
| 1990's | 3 (9.68) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (22.58) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Quon, BS | 1 |
| Goss, CH | 1 |
| Ramsey, BW | 2 |
| Tiddens, HA | 2 |
| De Boeck, K | 1 |
| Clancy, JP | 2 |
| Fayon, M | 1 |
| H G M, A | 1 |
| Bresnik, M | 2 |
| Derchak, A | 1 |
| Lewis, SA | 2 |
| Oermann, CM | 1 |
| Hansen, C | 1 |
| Skov, M | 1 |
| Rojo-Molinero, E | 1 |
| Macià, MD | 1 |
| Rubio, R | 1 |
| Moyà, B | 1 |
| Cabot, G | 1 |
| López-Causapé, C | 1 |
| Pérez, JL | 1 |
| Cantón, R | 1 |
| Oliver, A | 1 |
| Flume, PA | 1 |
| Retsch-Bogart, GZ | 1 |
| Tullis, DE | 1 |
| Derchak, PA | 1 |
| Ballmann, M | 1 |
| Smyth, A | 1 |
| Geller, DE | 1 |
| Littlewood, KJ | 1 |
| Higashi, K | 1 |
| Jansen, JP | 1 |
| Capkun-Niggli, G | 1 |
| Balp, MM | 1 |
| Doering, G | 1 |
| Angyalosi, G | 1 |
| Hollingsworth, JA | 1 |
| Donohoe, JF | 1 |
| Hone, R | 1 |
| Keelan, PJ | 1 |
| Pérez Pimiento, A | 1 |
| Gómez Martínez, M | 1 |
| Mínguez Mena, A | 1 |
| Trampal González, A | 1 |
| de Paz Arranz, S | 1 |
| Rodríguez Mosquera, M | 1 |
| Salh, B | 1 |
| Bilton, D | 1 |
| Dodd, M | 1 |
| Abbot, J | 1 |
| Webb, K | 1 |
| Bosso, JA | 3 |
| Black, PG | 2 |
| Schönwald, S | 1 |
| Schoss-Vidensek, Z | 1 |
| Car, V | 1 |
| Krznar, B | 1 |
| Boccazzi, A | 1 |
| Langer, M | 1 |
| Mandelli, M | 1 |
| Ranzi, AM | 1 |
| Urso, R | 1 |
| Shimada, K | 1 |
| Kawakami, Y | 2 |
| Abe, S | 2 |
| Saito, A | 3 |
| Nakayama, I | 1 |
| Tomizawa, M | 1 |
| Suzuki, A | 1 |
| Onodera, T | 1 |
| Yasuda, N | 1 |
| Koroku, T | 1 |
| Allen, JE | 1 |
| Saxon, BA | 1 |
| Matsen, JM | 1 |
| Neu, HC | 2 |
| Cook, JL | 1 |
| Lebel, MH | 1 |
| McCracken, GH | 1 |
| Takebe, K | 1 |
| Tamura, T | 1 |
| Endo, K | 1 |
| Irie, T | 1 |
| Sekino, K | 1 |
| Uehara, O | 1 |
| Sagara, M | 1 |
| Okamoto, K | 1 |
| Caramia, G | 1 |
| Compagnoni, L | 1 |
| Pettinari, A | 1 |
| Gregorini, S | 1 |
| LeFrock, JL | 1 |
| Smith, BR | 1 |
| Chandrasekar, P | 1 |
| Rolston, KV | 1 |
| Molavi, A | 1 |
| Kannangara, W | 1 |
| Sykes, RB | 1 |
| Bonner, DP | 1 |
| Swabb, EA | 1 |
| Henry, SA | 1 |
| Bendush, CB | 1 |
| Shimokata, K | 1 |
| Totani, Y | 1 |
| Morishita, M | 1 |
| Hashigami, H | 1 |
| Yamamoto, M | 1 |
| Suetsugu, S | 1 |
| Tanaka, A | 1 |
| Umeda, H | 1 |
| Sakai, S | 1 |
| Kobayashi, T | 1 |
| Shiba, K | 1 |
| Miyahara, T | 1 |
| Ueda, Y | 1 |
| Terai, T | 1 |
| Yamaguchi, E | 1 |
| Okazaki, N | 1 |
| Rodriguez, JR | 2 |
| Ramirez-Ronda, CH | 2 |
| Nevárez, M | 1 |
| Niino, M | 1 |
| Kida, K | 1 |
| Matsuda, H | 1 |
| Murase, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-label, Dose-escalation Study to Evaluate the Pharmacokinetics of Inhaled Teicoplanin in Cystic Fibrosis Patients[NCT04176328] | Phase 1 | 12 participants (Actual) | Interventional | 2019-10-25 | Completed | ||
| Open-Label Phase 2 Trial to Evaluate the Safety and Efficacy of Aztreonam 75 mg Powder and Solvent for Nebuliser Solution/Aztreonam for Inhalation Solution (AZLI) in Pediatric Patients With Cystic Fibrosis (CF) and New Onset Lower Respiratory Tract Cultur[NCT01375049] | Phase 2 | 105 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy (CAT) Regimen of Inhaled Antibiotics for the Treatment of Chronic Pulmonary Pseudomonas Aeruginosa I[NCT01641822] | Phase 3 | 107 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The percentage of participants with PA-negative cultures at all time points after cessation of active treatment at Day 28 (assessed at Days 56, 112, and 196) was summarized for the Evaluable Analysis Set. (NCT01375049)
Timeframe: Day 28 to Day 196
| Intervention | percentage of participants (Number) |
|---|---|
| AZLI - Evaluable Analysis Set | 58.2 |
The percentage of participants with PA-negative cultures at all time points after cessation of active treatment at Day 28 (assessed at Days 56, 112, and 196) was summarized for the Sensitivity Analysis Set. (NCT01375049)
Timeframe: Day 28 to Day 196
| Intervention | percentage of participants (Number) |
|---|---|
| AZLI - Sensitivity Analysis Set | 46.9 |
(NCT01375049)
Timeframe: Baseline to Days 28, 56, 112, and 196
| Intervention | kg/m^2 (Mean) | |||
|---|---|---|---|---|
| Change at Day 28 (On-Treatment, n = 104) | Change at Day 56 (Posttreatment, n = 101) | Change at Day 112 (Posttreatment, n = 90) | Change at Day 196 (Posttreatment, n = 69) | |
| AZLI | 0.1 | 0.1 | 0.0 | 0.0 |
Respiratory symptoms (eg, coughing, congestion, wheezing) were assessed with the Cystic Fibrosis Questionnaire - Revised (CFQ-R) Respiratory Symptoms Scale (RSS) only in participants ≥ 6 years of age. The range of scores (units) is 0 to 100 with higher scores indicating fewer symptoms. (NCT01375049)
Timeframe: Baseline to Days 28, 56, 112, and 196
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Change at Day 28 (n=24 [met], 29 [did not meet]) | Change at Day 56 (n=24 [met], 27 [did not meet]) | Change at Day 112 (n=24 [met], 21 [did not meet]) | Change at Day 196 (n=24 [met], 10 [did not meet]) | |
| AZLI - Did Not Meet Primary Efficacy Endpoint | 5.36 | 6.17 | 1.46 | 5.83 |
| AZLI - Met Primary Efficacy Endpoint | 8.33 | 6.37 | 5.79 | 6.13 |
Spirometry assessments were performed only in participants ≥ 6 years of age. Forced expiratory volume in 1 second (FEV1) % predicted was defined as FEV1 of the participant divided by the average FEV1 in the population for any person of similar age, sex and body composition. (NCT01375049)
Timeframe: Baseline to Days 28, 56, 112, and 196
| Intervention | percentage of FEV1% predicted (Mean) | |||
|---|---|---|---|---|
| Change at Day 28 (n=25 [met], 26 [did not meet]) | Change at Day 56 (n=25 [met], 26 [did not meet]) | Change at Day 112 (n=25 [met], 19 [did not meet]) | Change at Day 196 (n=25 [met], 8 [did not meet]) | |
| AZLI - Did Not Meet Primary Efficacy Endpoint | -0.38 | -4.24 | -5.10 | -8.85 |
| AZLI - Met Primary Efficacy Endpoint | -0.23 | -0.20 | 0.32 | -2.47 |
(NCT01375049)
Timeframe: Baseline to Days 28, 56, 112, and 196
| Intervention | cm (Mean) | |||
|---|---|---|---|---|
| Change at Day 28 (On-Treatment, n = 104) | Change at Day 56 (Posttreatment, n = 101) | Change at Day 112 (Posttreatment, n = 90) | Change at Day 196 (Posttreatment, n = 69) | |
| AZLI | 0.6 | 1.4 | 2.6 | 4.5 |
(NCT01375049)
Timeframe: Baseline to Days 28, 56, 112, and 196
| Intervention | kg (Mean) | |||
|---|---|---|---|---|
| Change at Day 28 (On-Treatment, n = 104) | Change at Day 56 (Posttreatment, n = 101) | Change at Day 112 (Posttreatment, n = 90) | Change at Day 196 (Posttreatment, n = 69) | |
| AZLI | 0.3 | 0.5 | 0.8 | 1.5 |
The percentage of participants with a PA-negative culture was summarized at each visit. (NCT01375049)
Timeframe: Days 28, 56, 112, and 196
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Day 28 | Day 56 | Day 112 | Day 196 | |
| AZLI | 89.1 | 75.2 | 63.4 | 47.5 |
The plasma concentration of aztreonam for participants < 6 years of age was obtained 1 hour after the first dose of AZLI on Day 1 and immediately prior to the last dose of AZLI on Day 28. (NCT01375049)
Timeframe: Day 1 (1 hour postdose) and Day 28 (immediately prior to dosing)
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Day 1 (1 hour postdose, n = 40) | Day 28 (immediately prior to dosing, n = 43) | |
| AZLI | 578 | 125 |
The percentage of participants who used additional (non-study) antipseudomonal antibiotics (an indication of PA exacerbation) while on treatment and posttreatment was summarized. (NCT01375049)
Timeframe: Baseline to Day 196
| Intervention | percentage of participants (Number) | |
|---|---|---|
| On-treatment | Posttreatment | |
| AZLI | 1.9 | 43.8 |
FEV1 % predicted is defined as FEV1 of the patient divided by the average FEV1 in the population for any person of similar age, sex and body composition. The adjusted mean is from a mixed-effect model repeated measures (MMRM) analysis. The model includes terms for baseline value, previous exacerbations (1, 2, ≥ 3), treatment, visit (categorical), and treatment by visit interaction. (NCT01641822)
Timeframe: Comparative Phase: Baseline and Weeks 4, 12 and 20
| Intervention | percentage of FEV1 % predicted (Mean) |
|---|---|
| AZLI | 1.37 |
| Placebo | 0.04 |
Respiratory symptoms (eg, coughing, congestion, wheezing) were assessed with the Cystic Fibrosis Questionnaire - Revised (CFQ-R) Respiratory Symptoms Scale (RSS). The range of scores (units) was 0 to 100 with higher scores indicating fewer symptoms. The adjusted mean is from a mixed-effect model repeated measures (MMRM) analysis. The model includes terms for baseline value, previous exacerbations (1, 2, ≥ 3), treatment, visit (categorical), and treatment by visit interaction. (NCT01641822)
Timeframe: Comparative Phase: Baseline and Weeks 4, 12 and 20
| Intervention | units on a scale (Mean) |
|---|---|
| AZLI | 1.00 |
| Placebo | -2.06 |
(NCT01641822)
Timeframe: Baseline in the comparative phase to the end of study (average time on study during the Comparative Phase: 155.4 days)
| Intervention | percentage of participants (Number) |
|---|---|
| AZLI | 48.8 |
| Placebo | 55.3 |
The rate of hospitalizations for a respiratory event per participant year was calculated using negative binomial regression analysis. (NCT01641822)
Timeframe: Baseline in the comparative phase to the end of study (average time on study during the Comparative Phase: 155.4 days)
| Intervention | hospitalizations per participant year (Number) |
|---|---|
| AZLI | 1.043 |
| Placebo | 1.624 |
PDEs were characterized by a change or worsening from baseline of 1 or more documented signs or symptoms (decreased exercise tolerance, increased cough, increased sputum or chest congestion, decreased appetite, or other signs or symptoms) associated with the use of non-study IV or inhaled antibiotics and be verified by a blinded independent adjudication committee. (NCT01641822)
Timeframe: Baseline in the comparative phase to the end of study (average time on study during the Comparative Phase: 155.4 days)
| Intervention | PDEs per participant year (Number) |
|---|---|
| AZLI | 1.309 |
| Placebo | 1.762 |
The time to first protocol-defined pulmonary exacerbation was calculated using the Kaplan-Meier method. (NCT01641822)
Timeframe: Baseline in the comparative phase to the end of study (average time on study during the Comparative Phase: 155.4 days)
| Intervention | days (Median) |
|---|---|
| AZLI | 175 |
| Placebo | 140.0 |
8 reviews available for aztreonam and Infections, Respiratory
| Article | Year |
|---|---|
Inhaled antibiotics for lower airway infections.
Topics: Administration, Inhalation; Amikacin; Amphotericin B; Anti-Bacterial Agents; Aztreonam; Ceftazidime; | 2014 |
Evidence for the efficacy of aztreonam for inhalation solution in the management of Pseudomonas aeruginosa in patients with cystic fibrosis.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Aztreonam; Cystic Fibrosis; Humans; Pseudomonas a | 2015 |
A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Aztreonam; Bacterial Load; Bay | 2012 |
The use of aztreonam in pediatric patients: a review.
Topics: Adult; Aztreonam; Bacterial Infections; Gram-Negative Aerobic Bacteria; Humans; Infant, Newborn; Men | 1991 |
Aztreonam: the first monobactam.
Topics: Aztreonam; Bacterial Infections; Gram-Negative Bacteria; Humans; Respiratory Tract Infections; Sepsi | 1988 |
Role of aztreonam in lower respiratory tract infections.
Topics: Aztreonam; Bacterial Infections; Cross Infection; Drug Evaluation; Gram-Negative Bacteria; Humans; I | 1988 |
Aztreonam: review of the clinical experience and potential uses in pediatrics.
Topics: Adolescent; Aztreonam; Bacterial Infections; Child; Child, Preschool; Cross Reactions; Cystic Fibros | 1988 |
Review of the clinical pharmacology of the monobactam antibiotic aztreonam.
Topics: Anti-Bacterial Agents; Aztreonam; Child; Drug Administration Schedule; Feces; Gram-Negative Aerobic | 1985 |
9 trials available for aztreonam and Infections, Respiratory
| Article | Year |
|---|---|
Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study.
Topics: Administration, Inhalation; Adolescent; Anti-Bacterial Agents; Aztreonam; Child; Child, Preschool; C | 2015 |
Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Aztreonam; Chronic Disease; Cy | 2016 |
Clinical experience with aztreonam in urinary and respiratory tract infections.
Topics: Adult; Aged; Anti-Bacterial Agents; Aztreonam; Clinical Trials as Topic; Escherichia coli Infections | 1984 |
A comparison of aztreonam and ceftazidime in the treatment of respiratory infections in adults with cystic fibrosis.
Topics: Adolescent; Adult; Aztreonam; Ceftazidime; Cystic Fibrosis; Double-Blind Method; Female; Forced Expi | 1992 |
[Clinical evaluation of carumonam in chronic respiratory infections: double-blind study using cefoperazone as a positive control].
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Aztreonam; Cefoperazone; Clinical Trials as Topic; D | 1987 |
Controlled trial of aztreonam vs. tobramycin and azlocillin for acute pulmonary exacerbations of cystic fibrosis.
Topics: Adolescent; Azlocillin; Aztreonam; Child; Cystic Fibrosis; Drug Therapy, Combination; Female; Humans | 1988 |
Aztreonam: worldwide overview of the treatment of patients with gram-negative infections.
Topics: Abdomen; Adult; Anti-Bacterial Agents; Arthritis, Infectious; Aztreonam; Bacterial Infections; Clini | 1985 |
[Clinical study of aztreonam on respiratory tract infections caused by gram-negative pathogens].
Topics: Adult; Aged; Aztreonam; Clinical Trials as Topic; Female; Gram-Negative Bacteria; Humans; Infusions, | 1985 |
Efficacy and safety of aztreonam-clindamycin versus tobramycin-clindamycin in the treatment of lower respiratory tract infections caused by aerobic gram-negative bacilli.
Topics: Aged; Anti-Bacterial Agents; Aztreonam; Bacteria, Aerobic; Clindamycin; Drug Therapy, Combination; F | 1985 |
14 other studies available for aztreonam and Infections, Respiratory
| Article | Year |
|---|---|
Sequential Treatment of Biofilms with Aztreonam and Tobramycin Is a Novel Strategy for Combating Pseudomonas aeruginosa Chronic Respiratory Infections.
Topics: Anti-Bacterial Agents; Aztreonam; Biofilms; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pse | 2016 |
Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics.
Topics: Administration, Inhalation; Aerosols; Anti-Bacterial Agents; Aztreonam; Chronic Disease; Cystic Fibr | 2011 |
Aztreonam and ceftazidime: evidence of in vivo cross allergenicity.
Topics: Aztreonam; Ceftazidime; Cephalosporins; Cross Reactions; Drug Hypersensitivity; Humans; Male; Middle | 1998 |
The clinical use of aztreonam.
Topics: Adult; Aged; Aztreonam; Bacterial Infections; Female; Humans; Male; Middle Aged; Respiratory Tract I | 1989 |
The pharmacokinetics of aztreonam and penetration into the bronchial secretions of critically ill patients.
Topics: Adolescent; Adult; Aged; Aztreonam; Bronchi; Critical Care; Female; Gram-Negative Bacteria; Humans; | 1989 |
Absence of rapidly developing resistance during treatment of cystic fibrosis patients with aztreonam.
Topics: Anti-Bacterial Agents; Aztreonam; Cystic Fibrosis; Drug Resistance, Microbial; Humans; Pseudomonas a | 1987 |
[Clinical study of carumonam].
Topics: Adult; Aged; Anti-Bacterial Agents; Aztreonam; Bacterial Infections; Female; Humans; Infusions, Intr | 1987 |
[Efficiency and possibility of the use of aztreonam in bacterial infections caused by gram-negative organisms].
Topics: Aztreonam; Child; Child, Preschool; Female; Gram-Negative Bacteria; Humans; Infant; Male; Respirator | 1986 |
Efficacy and safety of aztreonam in the treatment of serious gram-negative bacterial infections.
Topics: Adult; Aged; Aged, 80 and over; Aztreonam; Bacterial Infections; Female; Gram-Negative Bacteria; Hum | 1987 |
Aztreonam: the first monobactam.
Topics: Animals; Anti-Bacterial Agents; Aztreonam; Bacterial Infections; Bacterial Proteins; beta-Lactamases | 1985 |
[A comparative study between aztreonam and cefoperazone in respiratory tract infections].
Topics: Adolescent; Adult; Aged; Aztreonam; Cefoperazone; Female; Haemophilus influenzae; Humans; Male; Midd | 1985 |
Efficacy and safety of aztreonam versus tobramycin for aerobic gram-negative bacilli lower respiratory tract infections.
Topics: Anti-Bacterial Agents; Aztreonam; Bacterial Infections; Drug Administration Schedule; Drug Evaluatio | 1985 |
Current state of infectious diseases--potential areas of directed therapy with aztreonam.
Topics: Abdomen; Anti-Bacterial Agents; Arthritis, Infectious; Aztreonam; Bacterial Infections; Biliary Trac | 1985 |
[Clinical study on aztreonam in pediatrics].
Topics: Age Factors; Aztreonam; Child; Child, Preschool; Drug Evaluation; Enteritis; Female; Humans; Infant; | 1985 |